Across the recent three months, 9 analysts have shared their insights on Mirum Pharmaceuticals MIRM, expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 4 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $52.0, a high estimate of $72.00, and a low estimate of $35.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 2.42%.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Mirum Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Dae Gon Ha | Stifel | Announces | Buy | $48.00 | - |
| Ed Arce | HC Wainwright & Co. | Maintains | Buy | $58.00 | $58.00 |
| Mani Foroohar | Leerink Partners | Lowers | Outperform | $43.00 | $44.00 |
| Jonathan Wolleben | JMP Securities | Raises | Outperform | $72.00 | $69.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $58.00 | $45.00 |
| Josh Schimmer | Cantor Fitzgerald | Raises | Overweight | $40.00 | $35.00 |
| Ed Arce | HC Wainwright & Co. | Lowers | Buy | $45.00 | $58.00 |
| Jonathan Wolleben | JMP Securities | Raises | Market Outperform | $69.00 | $64.00 |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Overweight | $35.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Mirum Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mirum Pharmaceuticals compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Mirum Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Mirum Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Mirum Pharmaceuticals analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Mirum Pharmaceuticals's Background
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Mirum Pharmaceuticals: Financial Performance Dissected
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Mirum Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 149.24%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Mirum Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -51.27%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Mirum Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -13.77%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Mirum Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.24, Mirum Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
Understanding the Relevance of Analyst Ratings
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
